Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P49407

UPID:
ARRB1_HUMAN

ALTERNATIVE NAMES:
Arrestin beta-1; Non-visual arrestin-2

ALTERNATIVE UPACC:
P49407; B6V9G8; O75625; O75630; Q2PP20; Q9BTK8

BACKGROUND:
Beta-arrestin-1 functions as a key regulator in the GPCR signaling pathway, impacting receptor desensitization, resensitization, and internalization. It acts as a scaffold for various signaling cascades, including MAPK pathways, and modulates receptor-mediated signaling by transitioning GPCRs to beta-arrestin signaling modes. This protein's ability to recruit c-Src to receptors like ADRB2 for ERK activation underscores its multifaceted role in cellular signaling.

THERAPEUTIC SIGNIFICANCE:
Exploring Beta-arrestin-1's intricate role in cellular signaling and receptor dynamics offers a promising avenue for developing novel therapeutic interventions. Its central role in critical signaling pathways makes it a compelling target for drug discovery efforts aimed at modulating GPCR-mediated responses.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.